LOGIN  |  REGISTER
Amneal Pharmaceuticals

Regional Health Properties Regains Compliance with NYSE American Continued Listing Standards

February 24, 2023 | Last Trade: US$2.77 0.00 0.00

ATLANTA, GA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “we,” “us” or “our”) (NYSE American: RHE) (NYSE American: RHE-PA) announced today that the Company received a notice from the NYSE American LLC (the “Exchange”) on February 21, 2023 that the Company has regained compliance with the continued listing standard set forth in Section 704 of the NYSE American Company Guide. Specifically, the Company has resolved the continued listing deficiency with respect to its failure to hold an annual meeting of shareholders for the fiscal year ended December 31, 2021.

In the notification, the Exchange informed the Company that the below compliance (“BC”) indicator ceased to be disseminated on February 22, 2023. The Company was removed from the list of issuers noncompliant with NYSE American corporate governance listing standards posted on https://www.nyse.com/regulation/noncompliant-issuers and the BC indicator was removed from the profile, data and news pages of the Company’s security.

About Regional Health Properties

Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.

Company ContactInvestor Relations
Brent Morrison, CFABrett Maas
Chief Executive Officer & PresidentManaging Partner
Regional Health Properties, Inc.Hayden IR
Tel (678) 368-4402Tel (646) 536-7331
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.

Recursion

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page